Skip to main content
. 2021 Jan 19;40(7):2753–2761. doi: 10.1007/s10067-020-05558-7

Table 2.

Patient journey and treatment stratified by gender (N 2846, unless otherwise specified)

Men (n 1100)(mean ± SD or %) Women (n 1746)(mean ± SD or %) p value
Disease characteristics
  Age at onset of first symptoms (years), n 2721 27.0 ± 11.8 26.4 ± 10.7 0.342
  Age at diagnosis (years), n 2722 32.6 ± 12.2 34.4 ± 10.9 < 0.001
  Diagnostic delay (years), n 2652 6.1 ± 7.4 8.2 ± 8.9 < 0.001
  Disease Duration (years), n 2716 18.9 ± 13.3 16.1 ± 11.7 < 0.001
  HCP seen before diagnosis
  - General practitioner 822 (74.7) 1434 (82.1) < 0.001
    - Orthopaedic specialist 377 (34.3) 557 (31.9) 0.190
    - Physiotherapist 380 (34.5) 865 (49.5) < 0.001
    - Osteopath, n 2166 103 (13.3) 339 (24.4) < 0.001
    - Other, n 2220 135 (14.0) 233 (18.5) 0.005
  Family history of axSpA (yes), n 2244 291 (33.5) 584 (42.5) < 0.001
  HLA-B27 (positive), n 1799 497 (80.2) 786 (66.7) < 0.001
  Uveitis (yes), n 2096 199 (25.2) 270 (20.7) 0.023
  Inflammatory bowel disease (yes), n 2096 113 (14.3) 181 (13.9) 0.688
Treatment
  Pharmacological treatment
    - NSAIDs (without biologics), n 2319 324 (34.7) 533 (38.5) 0.068
    - Biologics (with or without NSAIDs), n 2316 359 (38.4) 594 (43.0) 0.024
  Alternative treatment (acupuncture, homoeopathy, etc.) (yes), n 2170 268 (34.3) 541 (38.9) 0.032

Bold values denote statistical significance at the p < 0.05 level